Arkolith/Insider Trading/TRVI/Form 4

Sciascia Thomas

Chief Scientific OfficerTrevi Therapeutics, Inc. (TRVI) · full profile →Form 4 · filed Mar 26, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$17K
Net Open-Market Flow
-$17K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 25, 2025Sell(S)3K$6.60$17K221K
Mar 25, 2025Option exercise(M)3K$1.43$4K224K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 25, 2025Option exercise(M)3K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-045295) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML